Akari Therapeutics Plc Quarterly Nonoperating Income (Expense) in USD from Q3 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Akari Therapeutics Plc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2014 to Q3 2024.
  • Akari Therapeutics Plc Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $32K.
  • Akari Therapeutics Plc Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$1.95M.
  • Akari Therapeutics Plc annual Nonoperating Income (Expense) for 2023 was $240K.
  • Akari Therapeutics Plc annual Nonoperating Income (Expense) for 2022 was -$1.31M, a 526% decline from 2021.
  • Akari Therapeutics Plc annual Nonoperating Income (Expense) for 2021 was -$210K, a 123% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$1.95M $32K +$396K Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-19
Q2 2024 -$2.35M -$687K +$2.59M +79% Apr 1, 2024 Jun 30, 2024 8-K 2024-09-06
Q1 2024 -$4.93M $423K -$5.17M -92.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $240K -$1.72M Oct 1, 2023 Dec 31, 2023 8-K 2024-09-06
Q3 2023 -$364K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-19
Q2 2023 -$3.27M -$3.41M -2504% Apr 1, 2023 Jun 30, 2023 8-K 2024-09-06
Q1 2023 $5.6M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q2 2022 $136K +$153K Apr 1, 2022 Jun 30, 2022 6-K 2022-09-27
Q2 2021 -$16.3K +$1.51M +98.9% Apr 1, 2021 Jun 30, 2021 6-K 2022-09-27
Q4 2020 $899K $85.7K +$89.4K Oct 1, 2020 Dec 31, 2020 20-F 2023-05-01
Q3 2020 $810K $1.16M +$925K +393% Jul 1, 2020 Sep 30, 2020 20-F 2021-04-21
Q2 2020 -$115K -$1.53M -$1.61M -1926% Apr 1, 2020 Jun 30, 2020 6-K 2021-09-22
Q1 2020 $1.5M $1.18M +$1.38M Jan 1, 2020 Mar 31, 2020 20-F 2021-04-21
Q4 2019 $117K -$3.71K Oct 1, 2019 Dec 31, 2019 20-F 2022-05-16
Q3 2019 $235K Jul 1, 2019 Sep 30, 2019 20-F 2021-04-21
Q2 2019 $83.7K +$127K Apr 1, 2019 Jun 30, 2019 20-F 2021-04-21
Q1 2019 -$198K Jan 1, 2019 Mar 31, 2019 20-F 2021-04-21
Q2 2018 -$43.3K -$7.07M -101% Apr 1, 2018 Jun 30, 2018 6-K 2019-08-29
Q2 2017 $7.03M +$5.96M +558% Apr 1, 2017 Jun 30, 2017 6-K 2018-09-27
Q2 2016 -$12.7M $1.07M +$1.1M Apr 1, 2016 Jun 30, 2016 6-K 2017-08-10
Q1 2016 -$13.8M $867K +$909K Jan 1, 2016 Mar 31, 2016 10-Q 2016-05-12
Q4 2015 -$14.7M $10.7M Oct 1, 2015 Dec 31, 2015 20-F 2018-07-18
Q3 2015 -$25.4M -$25.4M -498110% Jul 1, 2015 Sep 30, 2015 10-Q 2015-11-23
Q2 2015 -$28.8K Apr 1, 2015 Jun 30, 2015 6-K/A 2017-04-14
Q1 2015 -$42.2K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
Q3 2014 -$5.1K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.